Navigation Links
Colon cancer patients benefit from Hepatic Arterial Infusion Therapy

A new study conducted by Nancy E. Kemeny, MD, an Attending Physician in the Department of Medicine at Memorial Sloan-Kettering Cancer Center// said that patients whose colorectal cancer has spread to the liver fared better by receiving hepatic arterial infusion (HAI). In this technique chemotherapy was administered directly to the liver through a pump in the abdomen. It was found that the patients on the HAI therapy lived longer and had better quality of life than those receiving the traditional, intravenous chemotherapy. The results of the study were published in the Journal of Clinical Oncology.

This study demonstrated the effectiveness of the hepatic arterial infusion therapy. It showed that it extended the survival and improved the quality of life in patients with colorectal cancer that has spread to the liver. These findings are very important because statistics show that cancer metastasis to the liver occurs in 60 % of patients with metastatic colorectal cancer. This discovery will also reduce the number of deaths due to liver tumors.

The study was conducted by researchers from the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. The participants consisted of 135 patients who received either HAI or systemic chemotherapy. Prior to this all of the patients are needed to undergo surgical removal of their primary tumors in the colon. In case of patients receiving HAI then underwent an additional surgical procedure to have chemotherapy pump inserted into their abdomen.

Researchers found that patients receiving HAI lived longer (median survival rate of 24 months) than those receiving systemic chemotherapy. They also had better response rates (47 %) and longer time to disease progression in the liver (9.8 months).

On the other hand patients receiving systemic chemotherapy experienced various side effects such as diarrhea, decreased white blood cell counts, and hair loss. However, patients on the HAI regimen experienced mild toxicity to the liver.

In case of both the regimes women fared better than men, with median survival in the HAI group of 29.4 and 20.1 months for women and men, respectively, and in the systemic group it was 22.0 and 18.3 months.

This research was initiated in the year 1996, before the novel chemotherapy drugs such as irinotecan and oxaliplatin were available. In the study the patients received fluorouracil and leucovorin. Dr. Kemeny said that future studies are underway using HAI therapy in combination with newer drugs.


'"/>




Related medicine news :

1. Cancers of Colon & Rectum linked to Cigarette Smoking
2. Need for Colon cancer screening
3. Beer guards against Colon Cancer
4. Important substance in curry conciliate Inflamed Colon
5. Colon cancer linked with common virus
6. Colon cancer risk linked to genes causing Hemochromatosis
7. Death Risk Higher in Obese Women with Colon Cancer
8. Inflammation Linked to Colon Cancer
9. Aspirin Found To Reduce The Risk Of Colon Cancer
10. Blood Marker Found To Predict Colon Cancer
11. Estrogen Found To Protect the Colon Against Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, ... NET Foundation Summit from February 21 - 23 in Beaver Creek, CO. It was ... marks the Summit’s second year in Beaver Creek, hosting over 60 faculty members and ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon ... to families and business owners in the greater Fort Lauderdale metropolitan region, is ... , For more than 30 years, LifeNet 4 Families has provided a broad ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
(Date:2/16/2017)... ... February 17, 2017 , ... The Price Agency, ... families and entrepreneurs in the Birmingham area, is announcing an ongoing charity event ... with her medically challenged son, Anius. , Anius is medically complex with diagnoses ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Noble Capital Markets announced ... Pharma Inc. (Nasdaq: EPIX ). The report ... Kumar Raja , PhD. ESSA Pharmaceuticals is ... resistant prostate cancer (CRPC). Its lead compound EPI-506, is ... amino-terminal domain of the androgen receptor, thereby has potential ...
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... -- Newly published research from the CVS Health (NYSE: ... private retailer can play in restricting access to tobacco ... in the American Journal of Public Health , ... all CVS Pharmacy stores reduced the number of cigarette ... impact on those who bought cigarettes exclusively at CVS ...
Breaking Medicine Technology: